uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development
China-based advanced therapy medicinal product (ATMP) contract development and manufacturing organization (CDMO) uBriGene Biosciences announced...
uBriGene Biosciences
uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services
China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...
uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology...
uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy
China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...
uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation
China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...
Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy
US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...
Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform
Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...
Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...
Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...
Yiming and WZ Biosciences Collaborate on mRNA Process Platform
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...
Ubrigene Raises Hundreds of Millions in Series C Financing Round
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...